Skip to main content
Clinical Trials/CTRI/2021/04/032842
CTRI/2021/04/032842
Recruiting
未知

A Prospective, Randomized Controlled Single-Center, Two-Arm ( standard control), Open Label Investigator Initiated Clinical Study to Evaluate the Efficacy and Safety of Thymosin alpha 1 (T alpha1) and Ulinastatin in Sepsis Patients

Dr Abdul Ansari0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: A419- Sepsis, unspecified organism
Sponsor
Dr Abdul Ansari
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Abdul Ansari

Eligibility Criteria

Inclusion Criteria

  • 1 Male or females of greater than or equal to 18 years of age at the time of consent
  • 2 Patient who can and willing to provide written Informed Consent
  • 3 Patient Diagnosed as a sepsis according to the sepsis diagnosis criteria in Surviving Sepsis Campaign International Guidelines for Management of Sepsis 3 and Septic Shock 2016 Patient with at least one acute severe organ failure related to sepsis and total SOFA scores greater than or equal to 4
  • 4 Patient with confirmed or suspected infection and satisfy at least one of the following
  • a Pathogenic microbes grow in blood and at aseptic locations
  • b Presence of abscess or partially infected tissues
  • c Suspected infection identified by at least one of the following evidence
  • Leukocytes at aseptic locations CSF, blood, pleural fluid etc
  • Organ perforation confirmed by imaging evidence, examination result or intestinal content leak during drainage
  • Imaging evidence of pneumonia accompanied by purulent secretion and impaired gas exchange

Exclusion Criteria

  • 1 Patient less 18 years of age
  • 2 Patient having a medical history of allergy or intolerance to Thymosin alpha\-1 (T alpha1\) or Ulinastatin

Outcomes

Primary Outcomes

Not specified

Similar Trials